**PATENT** 

EV 048-195-093 US; Express Mail Number while the support of the su

#### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

BOX PATENT APPLICATION Assistant Commissioner of Patents Washington, D.C. 20231

### NON-PROVISIONAL APPLICATION TRANSMITTAL UNDER 37 CFR 1.53(b)

Transmitted herewith for filing is a non-provisional patent application:

Inventor(s) (or Application "Identifier"):

Laura C. Simmons Laura Klimowski Dorothea Reilly Daniel G. Yansura

Title: PROKARYOTICALLY PRODUCED ANTIBODIES AND USES THEREOF

## 1. Type of Application

- [ ] This application is for an original, non-provisional application.
- [x ] This is a non-provisional application claiming priority to provisional application no. 60/256,164 , filed <u>December 14, 2000</u>, the entire disclosure of which is hereby incorporated by reference.
- [ ] This is a [ ] continuation-in-part [ ] continuation [ ] divisional application claiming priority to application Serial Number\_\_, filed \_\_\_, the entire disclosure of which is hereby incorporated by reference.

# 2. Papers Enclosed Which Are Required For Filing Date Under 37 CFR 1.53(b) (Non-provisional)

- 73 pages of specification
- \_4 pages of claims
- \_\_\_\_\_ page of abstract
- 26 sheet(s) of drawings
  - [] formal [x] informal



4.

5.

## 3. Declaration or Oath

_X_	(for new and CIP applications; also for Cont./Div. where inventor(s) are being added) An unsigned declaration of the inventors is enclosed. A signed declaration of the inventors will follow.				
_	(for Cont./Div. where inventorship is the same or inventor(s) being deleted) A copy of the executed declaration/oath filed in the prior application is enclosed (37 CFR 1.63(d)).				
	(for Cont./Div. where inventor(s) being deleted) A signed statement is attached deleting inventor(s) named in the prior application (see 37 CFR 1.63(d)(2) and 1.33(b)).				
Assignment					
_x_	(for new and CIP applications)  x An Assignment of the invention to GENENTECH, INC. [] is enclosed with attached Recordation Form Cover Sheet [x] will follow.				
(for cont./div.) The prior application is assigned of record to Genentech, Inc.					
Ame	ndments (for continuation and divisional applications)				
	Cancel in this application original claims of the prior application before calculating the filing fee. (At least one original independent claim must be retained for filing purposes.)				
· · · · · ·	A preliminary amendment is enclosed. (Claims added by this amendment have been properly numbered consecutively beginning with the number next following the highest numbered original claim in the prior application.)				

## 6. Fee Calculation (37 CFR 1.16)

The fee has been calculated as follows:

No. of the last of		CLAIN	S FOR FEE CA	LCULATION	
Number	Fled	Laur 1880 Se Seu Steinneche, E. Substant	er Extra	Rate	
Total Claims	41	- 20 =	21	X \$18.00	\$378.00
Independent Claims	2	- 3=	0	X \$80.00	\$0.00
Multiple dependent claim(s), if any				+ \$270.00	\$0.00
Fi			ing Fee Calculation	\$1,118.00	

#### 7. Method of Payment of Fees

The Commissioner is hereby authorized to charge Deposit Account No. 07-0630 in the amount of \$1,118.00. A duplicate copy of this transmittal is enclosed.

### 8. Authorization to Charge Additional Fees

The Commissioner is hereby authorized to charge any additional fees required under 37 CFR §1.16 and 1.17, or credit overpayment to Deposit Account No. 07-0630. <u>A duplicate copy of this sheet is enclosed</u>.

#### 9. Additional Papers Enclosed

- [] Information Disclosure Statement (37 CFR §1.98) w/ PTO-1449 and citations
- Submission of "Sequence Listing", computer readable copy, certificate re: sequence listing, and/or amendment pertaining thereto for biological invention containing nucleotide and/or amino acid sequence.
- A new Power of Attorney or authorization of agent.
- Other:

# 10. Maintenance of Copendency of Prior Application (for continuation and divisional applications)

[This item must be completed and the necessary papers filed in the prior application	on if the period set
in the prior application has run]	•

	A petition, fee and/or response has been filed to extend the term in
	the pending prior application until
<del></del>	A copy of the petition for extension of time in the <i>prior</i> application
	is attached.

## 11. Correspondence Address:

X Address all future communications to:

Attn: Steven X. Cui

Respectfully submitted, GENENTECH, INC.

Date: December 13, 2001

Steven X. Cui Reg. No. 44,637

Telephone No. (650) 225-8674

09157

PATENT TRADEMARK OFFICE